PHASE II, OPEN LABEL, SINGLE DOSE STUDY OF THE SAFETY AND EFFICACY OF MNV-201 FOR THE TREATMENT OF PEARSON SYNDROME
Latest Information Update: 27 Jun 2025
At a glance
- Drugs MNV 201 (Primary)
- Indications Mitochondrial disorders
- Focus Adverse reactions
- Sponsors Minovia Therapeutics
Most Recent Events
- 31 Aug 2023 New trial record